



**Food and Drug Administration Advisory Committee Member  
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: Jeffrey R. Strawn, M.D., F.A.A.C.A.P.

Committee: Pediatric Advisory Committee

Meeting Date: September 15, 2020

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: discussion regarding acute hyperkinetic movement disorder associated with the combined use of ADHD stimulants and antipsychotics (including first-generation antipsychotics and second-generation antipsychotics), I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
<b>I. Personal/Immediate Family</b>		
Describe type of interest; e.g.: Stocks/investments; Employment; Work as consultant/advisor; Contracts/grants; Patents/royalties/trademarks; Work as an expert witness; Teaching/speaking/writing]	[Describe nature of interest; e.g.: sponsor, competitor, affected firm]	[Describe magnitude of interest; e.g.: \$ 0 - 5,000; \$5001- 10,000; \$10,001 -25,000; \$25,001 - 50,000)
<b>II Other Imputed Interests</b>		
Employment: contracts/grants	Product that will be used as an example in FDA public presentation	(b) (4)

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

**8/26/2020**

Signature

Date

/s/